A look ahead for the microbiome industry

03/27/19 • 16 min

We recently introduced listeners of Molecules, microbes and multiomics to our sister company, CoreBiome, a privately-held, Minnesota-based microbiome analysis company that accelerates discovery for customers in the pharmaceutical, agricultural, environmental and research communities. We are continuing this story via an interview with CoreBiome co-founder, Dr. Dan Knights.

In this new podcast, Dr. Knights speaks to us about why the microbiome is so different from the human genome, what answers microbiome research can provide for wellness and disease that we can’t find elsewhere, and what advice he would give an epidemiologist who is looking to add a microbiome component to their project.

Previous Episode

The microbiome challenges CoreBiome was built to solve

In the podcast, Dr. Dan Knights, co-founder and CEO of CoreBiome discusses the problems CoreBiome was built to solve and the challenges surrounding reproducibility in the microbiome field. You’ll learn why he “geeks out” about quality, efficiency, and accuracy and how his team keeps CoreBiome at the forefront of the microbiome industry. Learn more about CoreBiome and what it can do for microbiome researchers and clinicians here.

Next Episode

Urine as a liquid biopsy for cancer detection

We recently had the opportunity to visit our new sister company, Novosanis, in Antwerp, Belgium, to talk about urine as a sample type. Novosanis is dedicated to solving urine sampling challenges through its product Colli-PeeTM - an award-winning device designed to efficiently and hygienically capture first-void urine (the first 20ml of a urine sample). I spoke with their CEO and co-founder, Vanessa Vankerckhoven about the challenges first void urine collection solves for both cancer detection as well as STIs.